Second-line Therapies in PV: Determining the Optimal Strategy After Hydroxyurea Failure

In this downloadable slideset, Raajit K. Rampal, MD, PhD, reviews optimal second-line management strategies for patients with polycythemia vera, with a focus on those who have demonstrated an intolerance or inadequate response to hydroxyurea.
Raajit K. Rampal, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.63 MB
Released: December 14, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte

Related Content

On-demand webcast from a CAP satellite symposium on the role of pathology in myelodysplastic syndromes, from Clinical Care Options (CCO)

Tal Oren, MD, PhD Alexa J. Siddon, MD Cecilia Yeung, MD Released: November 28, 2022

Dr Jeff Sharman provides expert insight into the optimal treatment combinations in the management of CLL/SLL, from Clinical Care Options (CCO)

Jeff Sharman, MD Released: November 22, 2022

Video featuring an expert discussion of BTK inhibitors for CLL and MCL, from Clinical Care Options (CCO)

Matthew S. Davids, MD, MMSc Anthony Mato, MD, MSCE Jeff Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 22, 2022 Expired: November 21, 2023

Expert slides on nursing care for patients receiving CAR T-cells, including managing acute and long-term toxicities, from Clinical Care Options (CCO)

person default Kathryn Ciccolini, DNP, AGACNP-BC, OCN Linda Ramsdell, MSN, FNP-BC, OCN Released: November 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings